[ad_1]
Equity badysts predict Pacific Biosciences of California (NASDAQ: PACB) will post earnings per share of $ 0.17 for the current quarter According to Zacks reports, three badysts estimated the benefits of Pacific Biosciences of California: the highest estimate ($ 0.15) and the lowest ($ 0.18). Pacific Biosciences of California posted a profit of ($ 0.26) per share in the same quarter of last year, indicating a positive annual growth rate of 34.6% The company is expected to announce its next quarterly results on Wednesday, August 1st.
According to Zacks, badysts expect California Pacific Biosciences to release its annual report ($ 0.64) per share for the current fiscal year, with earnings-per-share estimates of its own. ranging from ($ 0.66) to ($ 0.59) for next year, badysts expect that the company will report a profit of ($ 0.47) per share, with estimates of EPS ranging from ($ 0.62) to ($ 0.30). Zacks Investment Research earnings per share calculations are based on a survey of research firms that follow Pacific Biosciences of California.
Pacific Biosciences of California (NASDAQ: PACB) released its financial results on Wednesday, May 2nd. The biotech company reported ($ 0.20) earnings per share (EPS) for the quarter, missing consensus badyst estimates of ($ 0.19) from ($ 0.01). Pacific Biosciences of California had a negative net margin of 105.22% and a negative return on equity of 91.11%. The company achieved a turnover of $ 19.40 million during the quarter, compared to the consensus estimate of $ 23.97 million. In the same quarter last year, the company posted earnings per share of $ 0.26. Company revenues declined 22.1% from one year to the next.
A number of brokerage firms recently participated in PACB. BidaskClub lowered Pacific Biosciences shares in California from a "strong buy" rating to a "buy" note in a report released on Saturday, June 30. ValuEngine has raised shares of California's Pacific Biosciences, rising from a "sell" note to a "sustaining" note in a report released on Saturday, June 2. Finally, Zacks Investment Research downgraded Pacific Biosciences of California shares from a "buy" rating to a "hold" rating in a report on Friday, May 25. Four equity research badysts gave a rating to the stock and another to the company. The company currently has an average "Hold" rating and an average price target of $ 4.52.
Institutional investors recently changed their equity holdings. Millennium Management LLC increased its holdings in Pacific Biosciences of California by 130.2% in the first quarter. Millennium Management LLC now holds 289,523 Biotech Company shares worth $ 594,000 after acquiring an additional 163,767 shares during the period. Point72 Asset Management LP acquired a new interest in Pacific Biosciences of California during the first quarter valued at $ 4,305,000. Blackstone Group LP increased its holdings in Pacific Biosciences of California by 71.0% in the first quarter. Blackstone Group LP now holds 4,123,571 shares of the biotechnology business worth $ 8,454,000 after acquiring 1,712,015 additional shares during the period. ART. Advisors LLC increased its holdings in Pacific Biosciences of California by 138.1% in the first quarter. ART. Advisors LLC now holds 192,196 shares of the $ 394,000 biotechnology business after acquiring an additional 111,468 shares during the period. Lastly, MetLife Investment Advisors LLC increased its holdings in Pacific Biosciences of California by 343.5% in the first quarter. MetLife Investment Advisors LLC now holds 58,747 shares in the $ 120,000 biotechnology business after acquiring an additional 45,502 shares during the period. 71.16% of the shares are held by institutional investors and hedge funds.
Pacific Biosciences shares in California fell by $ 0.02, reaching $ 3.67 during Friday, reports MarketBeat. The company had a trading volume of 391,300 shares, compared to its average volume of 1,091,687. The company has a debt ratio of 0.14, a ratio of 4.64 and a ratio of 3, 60. The company has a market capitalization of $ 486.63 million, a price / earnings ratio of -4.22 and a beta of 1.51. Pacific Biosciences of California has a minimum of $ 2.02 in one year and a high of $ 5.70 in one year.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to solve genetically complex problems. The company's single-molecule real-time sequencing (SMRT) technology enables real-time, single-molecule detection of biological processes. It offers PacBio RS II and Sequel systems that drive, monitor and badyze single molecule biochemical reactions in real time.
Get a free copy of Zacks' research report on Pacific Biosciences of California (PACB)
For more information on Zacks Investment Research's research offerings, visit Zacks.com
Receive news and Reviews of Pacific Biosciences of California Daily – Enter your email address below to receive a concise summary of the latest news and badyst ratings for Pacific Biosciences of California and related companies with the free daily newsletter MarketBeat.com.
Source link
